Alto Neuroscience, Inc.
Public company- Headquarters
- MOUNTAIN VIEW, California
- Ticker
- ANRO
- CIK
- 0001999480
WARN notices since 2024
Workers affected since 2024
Executive changes, last 12 months
Last event
Workers affected over time
Cumulative workers in WARN notices since 2024
Not enough notices to chart yet.
Leadership
| Role and person | Since | Change |
|---|---|---|
| President and Chief Financial OfficerNicholas C. Smith | Aug 27, 2026 | Appointed |
| PresidentAmit Etkin, M.D., Ph.D. | Aug 27, 2026 | Departed |
Related companies
Same industry and state, with recent events.
- ACADIA PHARMACEUTICALS INC
Executive Vice President, Head of Research and Development departs: Elizabeth H.Z. Thompson, Ph.D.
- KYNTRA BIO, INC.
Class III director appointed: Andrew E. Singer, MBA
- BIOMARIN PHARMACEUTICAL INC
WARN notice: Novato, CA
- CORCEPT THERAPEUTICS INC
President of Corcept Endocrinology departs: Sean Maduck
- Executive appointment
President and Chief Financial Officer appointed: Nicholas C. Smith
Nicholas C. Smith was named President and Chief Financial Officer of Alto Neuroscience, Inc., effective August 26, 2026. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Aug 27, 2026Role: President and Chief Financial Officer
- Executive departure
President departs: Amit Etkin, M.D., Ph.D.
Amit Etkin, M.D., Ph.D., President of Alto Neuroscience, Inc., departs the role, effective August 26, 2026. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Aug 27, 2026Role: President
Last verified Nov 8, 2026